News | December 01, 2008

Bracco Studies Support Products’ Clinical Safety and Efficacy

December 1, 2008 – At RSNA 2008, Bracco highlighted studies of its products that were the subject of multiple studies this past year, which reportedly demonstrated the company’s dedication to the manufacture of products that provide clinical safety and efficacy, including the following:

- The MR-ENHANCE study – a controlled multicenter double-blind randomized intraindividual crossover study design – published in the American Journal of Neuroradiology, suggests that the higher relaxivity of Bracco’s MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, may be linked to greater signal intensity, better contrast enhancement and better lesion conspicuity in MRI of the brain than gadodiamide.

- The PREDICT study (Patients with REnal impairment and DIabetes undergoing Computed Tomography), a prospective, randomized, double-blind comparison published in the American Journal of Roentgenology, reinforces the results of earlier published studies, IMPACT and CARE , in that it also failed to find a statistically significant difference in contrast-induced nephropathy (CIN) rates between iopamidol 370 mgl/mL (Isovue-370) and iodixanol 320 mgl/mL when administered in patients who are at high risk for a decline in renal function following the administration of intravascular contrast media.

- The ACRIN CT Colonography study published in The New England Journal of Medicine showcases the results from the largest multicenter trial on the efficacy of CT Colonography (CTC), also known as VC. With the use of Bracco’s PROTOCO2L, an automated carbon dioxide insufflation system for VC, and Tagitol V (barium sulfate suspension 40% w/v, 30% w/w) Bracco’s fecal tagging agent, researchers were able to demonstrate comparable accuracy for VC and standard colonoscopy. PROTOCO2L and Tagitol V were established as ACRIN clinical standards for use in VC.

- The Diagnostic Performance of PET Myocardial Perfusion Imaging study, a meta-analysis – published in Academic Radiology, provides a combined evaluation of numerous published studies in cardiac positron emission tomography (PET) MPI, confirming its excellent sensitivity and specificity in the diagnosis of coronary artery disease.

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...